Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma

References

• Tan D, Horning SJ, Hoppe RT, et al. Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University Experience. Blood. 2013;122(6):981–987.
   PubMed Web of Science ®Google Scholar
• Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol. 1993;20(5 Suppl 5):75–88.
   PubMed Web of Science ®Google Scholar
• Yang ZZ, Novak AJ, Ziesmer SC, et al. Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin's lymphoma. Cancer Res. 2009;69(13):5522–5530.
   PubMed Web of Science ®Google Scholar
• Guilloton F, Caron G, Menard C, et al. Mesenchymal stromal cells orchestrate follicular lymphoma cell niche through the CCL2-dependent recruitment and polarization of monocytes. Blood. 2012;119(11):2556–2567.
   PubMed Web of Science ®Google Scholar
• Coupland SE. The challenge of the microenvironment in B-cell lymphomas. Histopathology. 2011;58(1):69–80.
   PubMed Web of Science ®Google Scholar
• Sugimoto T, Watanabe T. Follicular lymphoma: the role of the tumor microenvironment in prognosis. J Clin Exp Hematop. 2016;56(1):1–19.
   PubMed Web of Science ®Google Scholar
• Devan J, Janikova A, Mraz M. New concepts in follicular lymphoma biology: from BCL2 to epigenetic regulators and non-coding RNAs. Semin Oncol. 2018;45(5-6):291–302.
   PubMed Web of Science ®Google Scholar
• Sagiv-Barfi I, Lu H, Hewitt J, et al. Intratumoral injection of TLR4 agonist (G100) leads to tumor regression of A20 lymphoma and induces abscopal responses. Blood. 2015;126(23):820–820.
   Web of Science ®Google Scholar
• Albershardt TC, Leleux J, Parsons AJ, et al. Intratumoral immune activation with TLR4 agonist synergizes with effector T cells to eradicate established murine tumors . NPJ Vaccines. 2020;5(1):50.
   PubMed Web of Science ®Google Scholar
• Lu H, Betancur A, Chen M, et al. Toll-like receptor 4 expression on lymphoma cells is critical for therapeutic activity of intratumoral therapy with synthetic TLR4 agonist glucopyranosyl lipid A. Front Oncol. 2020;10:1438.
   PubMed Web of Science ®Google Scholar
• Coler RN, Bertholet S, Moutaftsi M, et al. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLOS One. 2011;6(1):e16333.
   PubMed Web of Science ®Google Scholar
• Falloon J, Talbot HK, Curtis C, et al. Dose selection for an adjuvanted respiratory syncytial virus F protein vaccine for older adults based on humoral and cellular immune responses. Clin Vaccine Immunol. 2017;24(9):e00157–00117.
   PubMedGoogle Scholar
• Bhatia S, Miller NJ, Lu H, et al. Intratumoral G100, a TLR4 agonist, induces antitumor immune responses and tumor regression in patients with merkel cell carcinoma. Clin Cancer Res. 2019;25(4):1185–1195.
   PubMed Web of Science ®Google Scholar
• Mahipal A, Ejadi S, Gnjatic S, et al. First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1. Cancer Immunol Immunother. 2019;68(7):1211–1222.
   PubMed Web of Science ®Google Scholar
• Pollack SM. The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients. Expert Rev Vaccines. 2018;17(2):107–114.
   PubMed Web of Science ®Google Scholar
• Pishko A, Nasta SD. The role of novel immunotherapies in non-Hodgkin lymphoma. Transl Cancer Res. 2017;6(1):93–103.
   PubMed Web of Science ®Google Scholar
• Park HJ, Neelapu SS. Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials. Br J Haematol. 2008;142(2):179–191.
   PubMed Web of Science ®Google Scholar
• Timmerman JM, Vose JM, Czerwinski DK, et al. Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma. Leuk Lymphoma. 2009;50(1):37–46.
   PubMed Web of Science ®Google Scholar
• Palomba ML. Active immunotherapy: current state of the art in vaccine approaches for NHL. Curr Oncol Rep. 2012;14(5):433–440.
   PubMed Web of Science ®Google Scholar
• Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378):480–489.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412–7420.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–586.
   PubMed Web of Science ®Google Scholar
• Fowler N. Frontline strategy for follicular lymphoma: are we ready to abandon chemotherapy? Hematology Am Soc Hematol Educ Program. 2016;2016(1):277–283.
   PubMedGoogle Scholar
• Luminari S, Trotman J, Federico M. Advances in treatment of follicular lymphoma. Cancer J. 2020;26(3):231–240.
   PubMed Web of Science ®Google Scholar
• Marcus R, Davies A, Ando K, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017;377(14):1331–1344.
   PubMed Web of Science ®Google Scholar
• Kasi PM, Tawbi HA, Oddis CV, et al. Clinical review: serious adverse events associated with the use of rituximab - a critical care perspective. Crit Care. 2012;16(4):231.
   PubMed Web of Science ®Google Scholar
• Flowers CR, Leonard JP, Nastoupil LJ. Novel immunotherapy approaches to follicular lymphoma. Hematology Am Soc Hematol Educ Program. 2018;2018(1):194–199.
   PubMedGoogle Scholar
• Stenner F, Renner C. Cancer immunotherapy and the immune response in follicular lymphoma. Front Oncol. 2018;8:219.
   PubMed Web of Science ®Google Scholar
• Keytruda® product label. Whitehouse Station, NJ, USA; Merck Sharp & Dohme Corp. [cited 2020 Sept 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125514s034lbl.pdf
   Google Scholar
• Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med. 1996;2(1):52–58.
   Google Scholar
• Hilchey SP, Hyrien O, Mosmann TR, et al. Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab. Blood. 2009;113(16):3809–3812.
   PubMed Web of Science ®Google Scholar
• Bendandi M. Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures. Nat Rev Cancer. 2009;9(9):675–681.
   PubMed Web of Science ®Google Scholar
• Drobyski WR, Qazi R. Spontaneous regression in non-Hodgkin's lymphoma: clinical and pathogenetic considerations. Am J Hematol. 1989;31(2):138–141.
   PubMed Web of Science ®Google Scholar
• Merryman RW, Armand P, Wright KT, et al. Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma. Blood Adv. 2017;1(26):2643–2654.
   PubMed Web of Science ®Google Scholar
• Goodman A, Patel SP, Kurzrock R. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol. 2017;14(4):203–220.
   PubMed Web of Science ®Google Scholar
• Xu-Monette ZY, Zhou J, Young KH. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood. 2018;131(1):68–83.
   PubMed Web of Science ®Google Scholar
• Ansell SM. The highs and lows of immune-checkpoint blockade in lymphoma. Cancer Immunol Res. 2019;7(5):696–700.
   PubMed Web of Science ®Google Scholar
• Kline J, Godfrey J, Ansell SM. The immune landscape and response to immune checkpoint blockade therapy in lymphoma. Blood. 2020;135(8):523–533.
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–571.
   PubMed Web of Science ®Google Scholar
• Armand P, Janssens AM, Gritti G, et al. Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma. Blood. 2021;137(5):637–645.
   PubMed Web of Science ®Google Scholar
• Nastoupil LJ, Westin JR, Fowler NH, et al. Response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: Interim results of an on open-label, phase II study. J Clin Oncol. 2017;35(15_suppl):7519–7519.
   Google Scholar
• Westin JR, Chu F, Zhang M, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014;15(1):69–77.
   PubMed Web of Science ®Google Scholar
• Sutamtewagul G, Link BK. Novel treatment approaches and future perspectives in follicular lymphoma. Ther Adv Hematol. 2019;10:2040620718820510.
   Web of Science ®Google Scholar
• Bannerji R, Allan JN, Arnason JE, et al. Clinical activity of REGN1979, a bispecific human, anti-CD20 x anti-CD3 antibody, in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). Blood. 2019;134(Supplement_1):762–762.
   Web of Science ®Google Scholar
• Schuster SJ, Bartlett NL, Assouline S, et al. Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines. Blood. 2019;134(Supplement_1):6–6.
   PubMed Web of Science ®Google Scholar